JP2022528927A5 - - Google Patents

Info

Publication number
JP2022528927A5
JP2022528927A5 JP2021559827A JP2021559827A JP2022528927A5 JP 2022528927 A5 JP2022528927 A5 JP 2022528927A5 JP 2021559827 A JP2021559827 A JP 2021559827A JP 2021559827 A JP2021559827 A JP 2021559827A JP 2022528927 A5 JP2022528927 A5 JP 2022528927A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
domain
identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021559827A
Other languages
English (en)
Japanese (ja)
Other versions
JP7586833B2 (ja
JP2022528927A (ja
Filing date
Publication date
Priority claimed from GB1905150.7A external-priority patent/GB2589049C/en
Application filed filed Critical
Publication of JP2022528927A publication Critical patent/JP2022528927A/ja
Publication of JP2022528927A5 publication Critical patent/JP2022528927A5/ja
Application granted granted Critical
Publication of JP7586833B2 publication Critical patent/JP7586833B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021559827A 2019-04-11 2020-04-09 抗IgE抗体 Active JP7586833B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1905150.7A GB2589049C (en) 2019-04-11 2019-04-11 Anti-IgE antibodies
GB1905150.7 2019-04-11
PCT/EP2020/060240 WO2020208177A1 (en) 2019-04-11 2020-04-09 ANTI-IgE ANTIBODIES

Publications (3)

Publication Number Publication Date
JP2022528927A JP2022528927A (ja) 2022-06-16
JP2022528927A5 true JP2022528927A5 (cg-RX-API-DMAC7.html) 2023-04-18
JP7586833B2 JP7586833B2 (ja) 2024-11-19

Family

ID=66809886

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021559827A Active JP7586833B2 (ja) 2019-04-11 2020-04-09 抗IgE抗体

Country Status (16)

Country Link
US (3) US20220177604A1 (cg-RX-API-DMAC7.html)
EP (1) EP3953396A1 (cg-RX-API-DMAC7.html)
JP (1) JP7586833B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210150430A (cg-RX-API-DMAC7.html)
CN (1) CN113939540A (cg-RX-API-DMAC7.html)
AU (1) AU2020271405A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021020329A2 (cg-RX-API-DMAC7.html)
CA (1) CA3133941A1 (cg-RX-API-DMAC7.html)
EA (1) EA202192785A1 (cg-RX-API-DMAC7.html)
GB (1) GB2589049C (cg-RX-API-DMAC7.html)
IL (1) IL287035A (cg-RX-API-DMAC7.html)
MA (1) MA55600A (cg-RX-API-DMAC7.html)
MX (1) MX2021012457A (cg-RX-API-DMAC7.html)
PH (1) PH12021552545A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202110247XA (cg-RX-API-DMAC7.html)
WO (1) WO2020208177A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2992247T3 (es) 2020-01-08 2024-12-11 argenx BV Antagonistas del receptor de Fc neonatal humano (FcRn) para el tratamiento de trastornos del pénfigo
JP2024524614A (ja) 2021-07-14 2024-07-05 ライシア セラピューティクス, インコーポレイテッド Asgpr細胞表面受容体結合化合物及びコンジュゲート
US20260035484A1 (en) * 2021-10-29 2026-02-05 Longbio Pharma (Suzhou) Co., Ltd. Isolated antigen binding protein and use thereof
CN116262786B (zh) * 2021-12-13 2026-05-15 南京融捷康生物科技有限公司 针对folr1的单域抗体及其衍生蛋白和应用
KR20250037789A (ko) 2022-06-15 2025-03-18 아르젠엑스 비브이 Fcrn/항원-결합 분자 및 사용 방법
IL318098A (en) 2022-07-01 2025-02-01 Alk Abell? As IGE-FCER pushers
CN115724951B (zh) * 2022-11-15 2023-10-03 怡道生物科技(苏州)有限公司 与11型hpv结合的抗体或其抗原结合片段及其应用
EP4651901A1 (en) * 2023-01-18 2025-11-26 Lycia Therapeutics, Inc. Cycling lysosomal targeting antibody conjugates
CN118725128B (zh) * 2023-03-28 2025-09-16 东莞市朋志生物科技有限公司 抗IgE抗体、检测IgE的试剂和试剂盒
CN119490594B (zh) * 2023-08-15 2025-09-16 东莞市朋志生物科技有限公司 一种抗免疫球蛋白e的抗体及其应用
US20250101111A1 (en) * 2023-09-07 2025-03-27 argenx BV Fcrn antagonists and methods of use
GB202318512D0 (en) * 2023-12-04 2024-01-17 argenx BV Methods of determining potency
WO2025229206A1 (en) * 2024-05-03 2025-11-06 argenx BV Monovalent anti-iga binding molecules and methods of use
US20250353928A1 (en) 2024-05-17 2025-11-20 Excellergy, Inc. Antibodies and antibody fragments that bind ige
TW202604967A (zh) * 2024-06-07 2026-02-01 美商紐維格醫療公司 經修飾之Fc多肽
WO2026015664A1 (en) * 2024-07-10 2026-01-15 Lycia Therapeutics, Inc. Cycling lysosomal targeting chimeras targeting immunoglobulin e (ige)

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
US6725230B2 (en) 2000-07-18 2004-04-20 Aegis Analytical Corporation System, method and computer program for assembling process data of multi-database origins using a hierarchical display
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP1370288B1 (en) 2000-11-20 2012-01-11 Canadian Blood Services Method for treating thrombocytopenia with monoclonal ivig
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CA2487932A1 (en) 2002-05-30 2003-12-11 Macrogenics, Inc. Cd16a binding proteins and use for the treatment of immune disorders
PT1534335E (pt) 2002-08-14 2012-02-28 Macrogenics Inc Anticorpos específicos de fcγriib e processos para a sua utilização
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
ATE480562T1 (de) 2002-10-15 2010-09-15 Facet Biotech Corp Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2004204817C1 (en) 2003-01-13 2011-01-20 Macrogenics, Inc. Soluble FcyR fusion proteins and methods of use thereof
WO2004070010A2 (en) 2003-02-01 2004-08-19 Tanox, Inc. A method for generating high affinity antibodies
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
TWI667346B (zh) * 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
US20140294812A1 (en) * 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
CN106103476B (zh) 2013-12-24 2020-11-27 阿尔金克斯有限公司 FcRn拮抗剂及使用方法
EP4241852A3 (en) * 2014-04-30 2023-11-15 Hanall Biopharma Co., Ltd. Antibody binding to fcrn for treating autoimmune diseases
MX386491B (es) 2015-03-09 2025-03-18 argenx BV Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn.
GB201610198D0 (en) * 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
GB201707484D0 (en) 2017-05-10 2017-06-21 Argenx Bvba Method of preparing ph-dependent antibodies

Similar Documents

Publication Publication Date Title
US20250388700A1 (en) Variant fc regions
US20210040200A1 (en) Anti-ms4a4a antibodies and methods of use thereof
KR20190038607A (ko) 조작된 폴리펩티드 및 그의 용도
JP2018509413A5 (cg-RX-API-DMAC7.html)
CA3258002A1 (en) FCRN BINDING MOLECULES AND METHODS OF USE
CN106103476A (zh) FcRn拮抗剂及使用方法
CA3214283A1 (en) Anti-cd19 antibodies and car-t structures
TW202024132A (zh) Cd200r促效劑抗體及其用途
CN106574259A (zh) 新的抗人类Igβ抗体
US20250188161A1 (en) TGF-ß ANTIBODIES
WO2026076213A2 (en) Anti-hsa antibody fusions and methods of use thereof
US20260070982A1 (en) Antigen binding molecules to cd3 and cd19
US20240368283A1 (en) Molecules for modulating the immune system and uses thereof
WO2026102438A1 (en) Method for delivering fc fusion molecule
WO2026077414A1 (en) ANTIBODIES BINDING IL-7R Alpha AND USES THEREOF
EA049400B1 (ru) Антитела к ige
HK40058421A (en) Anti-ige antibodies
EA050049B1 (ru) Антитела к cd19 и car-t-клеточные структуры
WO2026064650A1 (en) Pd-1 binding proteins, vegf and pd-1 bispecific binding proteins, compositions, and methods of use
KR20260036311A (ko) IgG 관련 질환 및 장애의 치료를 위한 개선된 FcRn 길항제